CRP and cancer: Although the literature data regarding the utility of CRP as a biomarker in predicting Venous Thromboembolism (VTE) seem modest and conflicting, its clinical use seems improved in predicting VTE recurrence, cancer-associated thrombosis, and some other pathologies, as well as CVD and mortality in hemodialysis patients and the development of Vascular Access Thrombosis (VAT) in chronic hemodialysis individuals [276,277,278].